Pairs of tumor type and on-target therapeutic (tumor-clearing) CAR T cell are as follows: DIPG with GD2-CAR T19, ALL with CD19-CAR T25, aggressive osteosarcoma (engineered to express CD19)24 with CD19-CAR T, and rapid-clearing osteosarcoma with either GD2- or B7H3-CAR T. All CAR T cell constructs contain the 4–1BBz co-stimulatory domains24,26. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.